In conclusion, GLP-1RA is a promising candidate drug therapy for pediatric MASLD, and patients may benefit from metabolic improvement even if the liver disease ameliorating effects are not yet clear
4 min read If youve recently scrolled through any wellness or weight loss forums, youve likely seen talk about microdosing GLP-1 medications
Share this information with your healthcare team to inform treatment optimisation
They should also ask about protein intake, resistance training, hydration, constipation prevention, blood sugar monitoring, liver and kidney markers, and long-term maintenance after weight loss
Similar content being viewed by others Introduction The glucagon-like peptide-1 receptor (GLP-1R), is a prototypical class B GPCR involved in the regulation of glucose homeostasis, food intake, inflammation and hypertension [1, 2]
That comparison should have results by December 2026